Importantly, this finding was confirmed by EMSA assay, which shows that GRK5-NT significantly reduces both NFAT (Figure 4B) and GATA-4 (Figure 4C) ability to bind DNA in an established model of cardiac hypertrophy (i.e., SHR). Here, GATA4 is linked to cardiac hypertrophy.